Clinical trial
Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free…
NCT00289536 · Baxalta now part of Shire, Industry · Completed
Key facts
| NCT number | NCT00289536 |
|---|---|
| Title | Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A |
| Official title | Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (ADVATE rAHF-PFM): A Phase 4 Study to Determine the Pharmacokinetic Response of Patients Diagnosed With Severe Hemophilia A to Different Doses of ADVATE rAHF-PFM |
| Lead sponsor | Baxalta now part of Shire, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Biological |
| Interventions | Antihemophilic factor, recombinant, manufactured protein-free |
| Enrollment | 38 |
| Start date | Feb 2, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Feb 10, 2006 |
| Last update posted | Jun 10, 2021 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: